The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Timing and severity of skin-related adverse events in a phase II trial of sorafenib (BAY43-9006) in patients with advanced thyroid cancer.
Raya D. Terry
Research Funding - Bayer
Stephen Michael Keefe
Research Funding - Bayer
Carolyn Marie Grande
Research Funding - Bayer
Larisa Zifchak
Research Funding - Bayer
Marcia S. Brose
Consultant or Advisory Role - Bayer Schering Pharma; Bayer/Onyx
Honoraria - Bayer Schering Pharma
Research Funding - Bayer Schering Pharma; Bayer/Onyx